UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

October 12, 2022 (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

| Delaware | 1-11353 | 13-3757370 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 358 South Main Street | | |
| Burlington, North | Carolina | 27215 |
| (Address of principal executive offices | (3) | (Zip Code) |
| (Registrant's | s telephone number including area code) 336-2 | 29-1127 |
| Check the appropriate box below if the Form 8-K fills following provisions: | ng is intended to simultaneously satisfy the | filing obligation of the registrant under any of the |
| □ Written communication pursuant to Rule 425 under □ Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to R □ Pre-commencement communications pursuant to R Securities registered pursuant to Section 12(b) of the Excention | he Exchange Act (17 CFR 240.14a-12) ule 14d-2(b) under the Exchange Act (17 CFR ule 13e-4(c) under the Exchange Act (17 CFR | |
| 9 . | ne of exchange on which registered York Stock Exchange | |
| Indicate by check mark whether the registrant is an emerging chapter) or Rule 12b-2 of the Securities Exchange Act of Emerging growth company □ | | of the Securities Act of 1933 (§230.405 of this |
| If an emerging growth company, indicate by check mark or revised financial accounting standards provided pursua | | nded transition period for complying with any new |
| | | |
| | | |

Item 7.01 Regulation FD Disclosure

On October 12, 2022, Laboratory Corporation of America Holdings announced that its Board of Directors has declared a cash dividend in the amount of \$0.72 per share of common stock, to be paid on December 9, 2022 to the holders of record of all of the issued and outstanding shares of common stock as of the close of business on November 17, 2022. A copy of the press release announcing the dividend is furnished as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit Name

Exhibit 99.1 Press release dated October 12, 2022 issued by Labcorp

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>LABORATORY CORPORATION OF AMERICA HOLDINGS</u> Registrant

By: /s/ SANDRA VAN DER VAART

Sandra van der Vaart

Executive Vice President, Chief Legal Officer and Corporate Secretary

October 12, 2022



FOR IMMEDIATE RELEASE

Labcorp Contacts:

Investors: Chas Cook — 336-436-5076

Investor@Labcorp.com

Media: Rachael Valdez — 336-436-8263

Media@Labcorp.com

LABCORP DECLARES QUARTERLY DIVIDEND

BURLINGTON, N.C., Oct. 12, 2022 — Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of \$0.72 per share of common stock. The dividend will be payable on Dec. 9, 2022, to stockholders of record as of the close of business on Nov. 17, 2022.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of \$16 billion in FY2021. Learn more about us at www.labcorp.com or follow us on LinkedIn and Twitter @Labcorp.